Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

BACKGROUND: APF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h) chemotherapy-induced nausea and vomiting (CINV). In a phase III trial, APF530 was noninferior to palonosetron in preventing acute CINV following single-dose moderately (MEC) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccia, Ralph, O’Boyle, Erin, Cooper, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769519/
https://www.ncbi.nlm.nih.gov/pubmed/26921245
http://dx.doi.org/10.1186/s12885-016-2186-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769519/
https://www.ncbi.nlm.nih.gov/pubmed/26921245
http://dx.doi.org/10.1186/s12885-016-2186-4

Ejemplares similares